Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.
2.

Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.

Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM.

Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8. doi: 10.1128/AAC.01000-08. Epub 2009 Feb 2.

3.

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG, Back D.

AIDS. 1999 Nov 12;13(16):2239-50.

PMID:
10563709
4.

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.

Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M.

Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19.

5.

Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.

Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, Mahony WB, Hutman HW.

J Clin Pharmacol. 2001 Mar;41(3):277-88.

PMID:
11269568
6.

Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.

Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA; COL10053 Study Team.

Antimicrob Agents Chemother. 2007 Feb;51(2):560-5. Epub 2006 Nov 6.

7.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
8.

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

Bruno R, Regazzi MB, Ciappina V, Villani P, Sacchi P, Montagna M, Panebianco R, Filice G.

Clin Pharmacokinet. 2001;40(9):695-700.

PMID:
11605717
10.
11.

Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.

Flynn PM, Rodman J, Lindsey JC, Robbins B, Capparelli E, Knapp KM, Rodriguez JF, McNamara J, Serchuck L, Heckman B, Martinez J; PACTG P1012 Team.

Antimicrob Agents Chemother. 2007 Oct;51(10):3516-22. Epub 2007 Jul 30.

12.

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.

Moore KH, Shaw S, Laurent AL, Lloyd P, Duncan B, Morris DM, O'Mara MJ, Pakes GE.

J Clin Pharmacol. 1999 Jun;39(6):593-605.

PMID:
10354963
13.

Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.

Ye M, Wang L, Fu Q, Zhu Z, Li P, Li T.

HIV Clin Trials. 2010 Jul-Aug;11(4):230-7. doi: 10.1310/hct1104-230.

PMID:
20974578
14.
15.

Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.

Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, Kashuba AD.

AIDS. 2007 Jan 2;21(1):59-64.

PMID:
17148968
16.

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.

J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.

PMID:
19776037
18.

Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.

Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA.

Antimicrob Agents Chemother. 2006 Jul;50(7):2309-15.

19.
20.

Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.

Jenner P, Könen-Bergmann M, Schepers C, Haertter S.

Clin Ther. 2009 Nov;31(11):2698-711. doi: 10.1016/j.clinthera.2009.10.018.

PMID:
20110012

Supplemental Content

Support Center